- Home
- QSI vs PCRX Comparison
QSI vs PCRX Comparison
Compare QSI & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- PCRX
- Stock Information
- Founded
- QSI 2013
- PCRX 2006
- Country
- QSI United States
- PCRX United States
- Employees
- QSI N/A
- PCRX N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- PCRX Health Care
- Exchange
- QSI Nasdaq
- PCRX Nasdaq
- Market Cap
- QSI 633.2M
- PCRX 604.7M
- IPO Year
- QSI N/A
- PCRX 2011
- Fundamental
- Price
- QSI $2.38
- PCRX $22.23
- Analyst Decision
- QSI Buy
- PCRX Buy
- Analyst Count
- QSI 2
- PCRX 10
- Target Price
- QSI $3.25
- PCRX $27.60
- AVG Volume (30 Days)
- QSI 59.3M
- PCRX 787.3K
- Earning Date
- QSI 02-27-2025
- PCRX 02-27-2025
- Dividend Yield
- QSI N/A
- PCRX N/A
- EPS Growth
- QSI N/A
- PCRX N/A
- EPS
- QSI N/A
- PCRX N/A
- Revenue
- QSI $2,266,000.00
- PCRX $694,957,000.00
- Revenue This Year
- QSI $193.90
- PCRX $4.83
- Revenue Next Year
- QSI $173.18
- PCRX $2.16
- P/E Ratio
- QSI N/A
- PCRX N/A
- Revenue Growth
- QSI 232.26
- PCRX 4.40
- 52 Week Low
- QSI $0.61
- PCRX $11.16
- 52 Week High
- QSI $5.77
- PCRX $34.01
- Technical
- Relative Strength Index (RSI)
- QSI 51.42
- PCRX 71.48
- Support Level
- QSI $2.20
- PCRX $18.18
- Resistance Level
- QSI $2.68
- PCRX $22.88
- Average True Range (ATR)
- QSI 0.71
- PCRX 1.14
- MACD
- QSI -0.13
- PCRX 0.32
- Stochastic Oscillator
- QSI 15.69
- PCRX 96.36
About QSI Quantum-Si Incorporated
Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.